whytestocks
4 years ago
News: $VNRX Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test
AUSTIN, Texas , July 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company applying its Nu.Q™ Nucleosomics™ technology to develop simple, cost effective blood-based tests for cancer and other diseases, today...
In case you are interested VNRX - Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test
XenaLives
5 years ago
I suspect the patent is about more than COVID...
Introduction
Neutrophils are the most abundant leukocytes in mammals and, as a first line of defense against microbes, they play crucial roles in innate immune responses. The homeostasis of neutrophils is maintained by balancing their short lifespan in the circulation with their regulated release from the bone marrow. Neutrophils have various types of granules, containing hundreds of proteins. These include bactericidal proteins, some of them with important effects on innate and adaptive immune responses, such as a-defensins, the cathelicidin human cationic antimicrobial protein of 18 kDa, and lactoferrin, among others. LL-37, a proteolytic product of human cationic antimicrobial protein of 18 kDa, has important chemotactic and immunostimulatory effects, as discussed below (1).
The mechanisms used by neutrophils to eliminate microbes include phagocytosis, generation of reactive oxygen species (ROS), and the release of microbicidal molecules from granules (degranulation). In 2004, another distinct antimicrobial activity was described: neutrophils extrude a meshwork of chromatin fibers that are decorated with granule-derived antimicrobial peptides and enzymes such as neutrophil elastase (Fig. 1), cathepsin G, and myeloperoxidase (MPO) (2). These structures, called neutrophil extracellular traps (NETs), represent an important strategy to immobilize and kill invading microorganisms. The NET scaffold consists of chromatin fibers with a diameter of 15β17 nm; DNA and histones represent the major NET constituents (2). Mass spectrometry has identified various additional proteins associated with NETs, including components from various types of granules. Although conserved proteins are found in extracellular trap fractions, it is still unclear whether the peptide composition of these structures may vary depending on the specific stimulus that promotes NET formation (3, 4).
Cont..
https://www.jimmunol.org/content/189/6/2689.long
XenaLives
5 years ago
4/23/20 - Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies
AUSTIN, Texas, April 23, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, using its propriety Nu.QTM platform. The goal of the test is to provide early insight into which patients may require higher levels of monitoring including hospitalization and critical care resources, versus those who will not develop serious symptoms. Preliminary studies of patients with COVID-19 infection are now underway in hospitals in Belgium and Germany with results expected this quarter.
Full PR:
https://finance.yahoo.com/news/volition-files-patent-nu-q-123000672.html
XenaLives
5 years ago
Eavesdropping:
Labsolute wrote on 21.05.20 17:25:37 Entry No. 1.785 (63.763.840) Reply to entry no .: 63.763.585 by tycoon111 am 05/21/20 16:55:36 I am optimistic from the bottom up and may be concerned with my investments, maybe that's the reason And: the burn rate is great, nothing is too high !! Capital increases are also absolutely normal for such companies. Volition has never had any problems getting fresh cash in the past and has always been supported by the state. You can not be blamed for burning the shareholders' money senselessly! And slowly what needs to be monetized is your opinion as so I take on young impatient small shareholders. I see the data that was published a week ago and I know that such a diagnosis no other company in the world can - not at Stage1 and not at the price and time required. And in my opinion it will stay that way for a long time! I do not know whether the price climbs up or down as your question was - but I see a ridiculous market capitalization which can only increase tenfold in the short term (vet / Lung china / COVID) with just one successful piece of the puzzle and on the other hand I see a stable balance sheet a lot of cash and competitors who all still need a lot of time! So an excellent change risk ratio, even if small cap very risky!
Labsolute wrote on 23.05.20 14:18:01 Entry No. 1.789 (63.779.455) no topic - welcome to high risk - high reward. You have to get along with the Vola - especially difficult as an ETF investor. Always think of fear vs greed and rationally rethink everything in difficult phases. We are in a wild market phase: from V-recovery to deepest depression, everything is in the room - if you have already felt uncomfortable, rethink the position size. Otherwise there is now more than enough cash in the company to survive this phase and we can look forward to further data and news this year. Reynolds directly secured a small package for $ 2.75. Think that calms many people again.
https://www.wallstreet-online.de/diskussion/1275261-1781-1790/bluttest-krebserkennung-valitionrx-was
XenaLives
5 years ago
Only 8% insty ownership but this bears looking into:
2020-05-07 13D/A Eight Corp Ltd 12,045,332 29.20
2019-08-01 13D Cotterford Co Ltd 12,041,570 29.30
2019-02-25 13G/A Hever Investments Ltd 11,877,476 29.40
2019-02-14 13G/A Lagoda Investment Management, L.P. 1,643,714 4.70
2019-02-11 13D/A Innes Guy Archibald 1,875,701 5.30
2018-11-09 13D/A Faulkes Martin Charles 1,977,284 5.60
2018-11-09 13D/A Reynolds Cameron John 2,562,967 7.20
2017-02-08 13G/A MANCHESTER MANAGEMENT CO LLC 1,212,159 4.60
2016-12-29 13D Hunt David 63,440,000 62.30
whytestocks
5 years ago
News: $VNRX Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes
AUSTIN, Texas , Sept. 17, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.Q TM Capture development program: the ability to enrich nucleosomes, and therefore, DNA of tumor versus non-tumor origin....
Find out more VNRX - Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes